Linezolid for the treatment of adults with bone and joint infections.
We reviewed the available evidence regarding the effectiveness and safety of linezolid administration for the treatment of patients with orthopaedic infections due to multidrug-resistant Gram-positive cocci. Although the reports published to date include promising results for the use of linezolid for bone and joint infections, controlled studies will be needed to reach safe conclusions. Attention should be paid to adverse effects that may be related to linezolid administration, especially bone marrow suppression with prolonged administration of the antibiotic. In addition, early identification of linezolid-induced peripheral neuropathy is necessary because this may be an irreversible event.
Falagas
Matthew E
ME
Alfa Institute of Biomedical Sciences (AIBS), Athens, Greece. matthew.falagas@tufts.edu
Siempos
Ilias I
II
Papagelopoulos
Panayiotis J
PJ
Vardakas
Konstantinos Z
KZ
D000081:Acetamides / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000328:Adult; D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001170:Arthritis, Infectious / Q000188:drug therapy*; D024901:Drug Resistance, Multiple, Bacterial; D016908:Gram-Positive Bacterial Infections / Q000188:drug therapy*; D006095:Gram-Positive Cocci / Q000187:drug effects; D006801:Humans; D000069349:Linezolid; D010019:Osteomyelitis / Q000188:drug therapy*; D023303:Oxazolidinones / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced
D000081:Acetamides; D000900:Anti-Bacterial Agents; D023303:Oxazolidinones; D000069349:Linezolid